年龄校正合并症指数与局部晚期喉癌生存的关系
本研究纳入548例局部晚期喉癌患者,中位年龄59岁,58%接受喉保留治疗,其余行全喉切除加辅助放疗。
要点
- 年龄校正CCI≤3组5年总生存率60%,优于CCI>3组的41%。
- 两组5年疾病特异性生存率无显著差异。
- 年龄校正CCI是非癌特异性生存和总生存的显著预测因子。
核心结论
- 年龄校正CCI是局部晚期喉癌患者非癌特异性生存和总生存的显著预测因子,但与疾病特异性生存无关。
研究设计与样本
- 回顾性队列研究,纳入548例局部晚期喉癌患者,收集基线合并症数据并计算年龄校正CCI,采用Kaplan-Meier和Cox比例风险模型分析生存关联。
主要发现
- 548例患者中位年龄59岁(范围31-91岁),58%接受喉保留治疗,其余行全喉切除加辅助放疗。
- 5年疾病特异性生存率两组无显著差异。
关键数值与推荐
- 5年疾病特异性生存率两组无显著差异。
临床怎么用
- 对局部晚期喉癌患者,应评估年龄校正CCI以识别非癌死亡高风险者,辅助治疗决策和随访管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The purpose of this study was to quantify the relationship among age, pretreatment comorbidity, and survival outcomes in patients with locally advanced laryngeal cancer. METHODS: Baseline comorbidity data were collected and age-adjusted Charlson Comorbidity Index (CCI) was calculated for each case. Kaplan-Meier and Cox proportional hazards modeling were used to determine associations with survival. RESULTS: For 548 patients, with a median age of 59 years (range 31-91 years), 58% were treated with larynx preservation and the rest with total laryngectomy and adjuvant radiotherapy (RT). Two hundred thirty-eight patients (43%) had at least 1 comorbidity each. Cardiovascular diseases were the most common comorbidities (19%). The 5-year overall survival (OS) for patients with CCI ≤3 (n = 442) were superior to CCI >3 (n = 106; 60% vs 41%; P < .0001), although the 5-year disease-specific survival (DSS) rates were not significantly different. The 5-year noncancer CSS was better for age-adjusted CCI ≤3 (88% vs 67%; P < .0001). CONCLUSION: The age-adjusted CCI is a significant predictor of noncancer CSS and OS for patients with locally advanced laryngeal cancer but is not associated with DSS.
引用
- Mulcahy CF, Mohamed ASR, Kanwar A, et al. Age-adjusted comorbidity and survival in locally advanced laryngeal cancer. Head Neck. 2018. PMID: 29756307. doi:10.1002/hed.25200
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。